Cellectis (CLLS) Long-Term Debt Issuances (2020 - 2024)
Cellectis (CLLS) posted Long-Term Debt Issuances of $6.9 million for Q4 2024, up 6158.18% on a QoQ basis from $110000.0 in Q3 2024, and up 395.61% year-over-year from $1.4 million in Q1 2024.
Cellectis (CLLS) has 4 years of Long-Term Debt Issuances data on file, last reported at $6.9 million in Q4 2024.
- In Q4 2024, Long-Term Debt Issuances rose 395.61% year-over-year to $6.9 million; the TTM figure through Dec 2024 stood at $23.2 million (up 234.07% YoY), while the FY2024 annual figure was $23.2 million, down 21.81% from the prior year.
- Long-Term Debt Issuances rose to $6.9 million in Q4 2024, from $110000.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $22.3 million in Q3 2020 and bottomed at -$158000.0 in Q3 2022.
- A 4-year average of $5.3 million and a median of $1.4 million in 2023 frame the typical range for Long-Term Debt Issuances.
- Annual changes were most pronounced in 2023 — Long-Term Debt Issuances soared 3755.06% — and 2024, when it slumped 98.1%.
- Year by year, Long-Term Debt Issuances stood at $22.3 million in 2020, then plunged by 100.27% to -$61000.0 in 2022, then surged by 2377.05% to $1.4 million in 2023, then jumped by 395.61% to $6.9 million in 2024.
- The last three Long-Term Debt Issuances figures came in at $6.9 million (Q4 2024), $110000.0 (Q3 2024), and -$44000.0 (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.73 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 6.88 Mn |
| Dec 31, 2024 | 6.88 Mn |
| Sep 30, 2024 | 110,000.00 |
| Sep 30, 2024 | 110,000.00 |
| Jun 30, 2024 | -44,000.00 |
| Jun 30, 2024 | -44,000.00 |
| Mar 31, 2024 | 16.25 Mn |
| Mar 31, 2024 | 16.25 Mn |
| Dec 31, 2023 | 1.39 Mn |
| Dec 31, 2023 | 1.39 Mn |
| Sep 30, 2023 | 5.78 Mn |
| Sep 30, 2023 | 5.78 Mn |
| Dec 31, 2022 | -61,000.00 |
| Dec 31, 2022 | -61,000.00 |
| Sep 30, 2022 | -158,000.00 |
| Sep 30, 2022 | -158,000.00 |
| Jun 30, 2022 | 6.00 Mn |
| Jun 30, 2022 | 6.00 Mn |
| Mar 31, 2022 | -30,000.00 |
| Mar 31, 2022 | -30,000.00 |
| Sep 30, 2020 | 22.33 Mn |
| Sep 30, 2020 | 22.33 Mn |